Provide a genomic-based, comprehensive, individualized risk assessment for early-stage cancers in specific settings.
Inform treatment options for those facing the challenges of advanced-stage cancer.
Understand how genomic testing can help to guide your individualized treatment options.
mdxhealth has acquired the Oncotype DX Genomic Prostate Score (GPS) test from Exact Sciences. Exact Sciences will continue to perform the GPS test during the transition.
Receive occasional email about genomic testing and our products, including the latest research and reports.
Email Customer Service
You are now leaving this site. Any third party link you select from this site may take you to a website that is not affiliated with Exact Sciences.